|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_once
|
monthly
|
|
gptkbp:approves
|
gptkb:2018
gptkb:FDA
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:chemical_formula
|
C_40 H_57 N_7 O_12 S
|
|
gptkbp:clinical_trial
|
gptkb:EVOLVE-1
gptkb:EVOLVE-2
Phase III
REGAIN
|
|
gptkbp:contraindication
|
hypersensitivity to galcanezumab
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:distribution_volume
|
large
|
|
gptkbp:excretion
|
primarily through the reticuloendothelial system
|
|
gptkbp:formulation
|
solution for injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
galcanezumab
|
|
gptkbp:indication
|
chronic migraine
episodic migraine
|
|
gptkbp:invention
|
patented
|
|
gptkbp:lifespan
|
about 27 days
|
|
gptkbp:marketed_as
|
gptkb:Emgality
|
|
gptkbp:mechanism_of_action
|
CGRP receptor antagonist
|
|
gptkbp:route_of_administration
|
subcutaneous injection
|
|
gptkbp:side_effect
|
fatigue
nausea
constipation
injection site reactions
hypersensitivity reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
CGRP (Calcitonin Gene-Related Peptide)
|
|
gptkbp:used_for
|
migraine prevention
|
|
gptkbp:weight
|
887.0 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Emgality
|
|
gptkbp:bfsLayer
|
5
|